MINI, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 32.845
EU - Europa 21.490
AS - Asia 16.929
SA - Sud America 2.472
Continente sconosciuto - Info sul continente non disponibili 621
AF - Africa 434
OC - Oceania 318
AN - Antartide 1
Totale 75.110
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 32.215
RU - Federazione Russa 6.991
SG - Singapore 4.687
CN - Cina 4.421
IT - Italia 4.238
PL - Polonia 3.863
HK - Hong Kong 2.337
BR - Brasile 1.970
IE - Irlanda 1.849
KR - Corea 1.713
VN - Vietnam 1.680
SE - Svezia 1.097
DE - Germania 748
FR - Francia 649
FI - Finlandia 642
IN - India 569
UA - Ucraina 460
GB - Regno Unito 420
CA - Canada 380
JP - Giappone 346
AU - Australia 308
JO - Giordania 254
AR - Argentina 200
ID - Indonesia 170
BD - Bangladesh 164
TR - Turchia 127
MX - Messico 105
EC - Ecuador 97
ES - Italia 94
NG - Nigeria 92
CH - Svizzera 91
IQ - Iraq 90
NL - Olanda 87
ZA - Sudafrica 84
CI - Costa d'Avorio 63
CO - Colombia 61
AT - Austria 57
BE - Belgio 52
MA - Marocco 43
PK - Pakistan 43
VE - Venezuela 41
TH - Thailandia 39
CL - Cile 33
PH - Filippine 33
SA - Arabia Saudita 30
EG - Egitto 27
AE - Emirati Arabi Uniti 26
BJ - Benin 26
PY - Paraguay 26
UZ - Uzbekistan 25
MY - Malesia 24
PE - Perù 24
JM - Giamaica 23
KE - Kenya 19
LT - Lituania 18
NP - Nepal 18
AL - Albania 17
CR - Costa Rica 17
SC - Seychelles 17
TN - Tunisia 17
TW - Taiwan 17
CZ - Repubblica Ceca 15
DZ - Algeria 15
HN - Honduras 15
TT - Trinidad e Tobago 14
UY - Uruguay 14
DO - Repubblica Dominicana 13
IL - Israele 13
IR - Iran 12
LB - Libano 12
SY - Repubblica araba siriana 12
GR - Grecia 11
RS - Serbia 11
AZ - Azerbaigian 10
ET - Etiopia 10
GT - Guatemala 10
KZ - Kazakistan 10
NZ - Nuova Zelanda 10
SV - El Salvador 10
DK - Danimarca 9
OM - Oman 9
PA - Panama 9
PR - Porto Rico 8
RO - Romania 8
BG - Bulgaria 7
PT - Portogallo 7
BB - Barbados 6
EE - Estonia 6
GE - Georgia 5
HR - Croazia 5
LV - Lettonia 5
MD - Moldavia 5
MK - Macedonia 5
NI - Nicaragua 5
NO - Norvegia 5
PS - Palestinian Territory 5
BO - Bolivia 4
BY - Bielorussia 4
CY - Cipro 4
EU - Europa 4
Totale 74.416
Salva come PNG Salva come JPEG
Città #
Santa Clara 6.094
Warsaw 3.830
Ashburn 3.440
Singapore 3.391
Fairfield 2.104
Hong Kong 1.871
Dublin 1.841
Seoul 1.658
Chandler 1.603
San Jose 1.547
Hefei 1.369
Woodbridge 971
Seattle 879
Cambridge 870
Milan 827
Houston 821
Wilmington 761
Jacksonville 700
Beijing 660
Council Bluffs 653
Ho Chi Minh City 542
Los Angeles 522
Ann Arbor 453
The Dalles 447
Buffalo 434
Lauterbourg 430
Florence 384
Princeton 382
Hanoi 374
Rome 372
Altamura 366
Lawrence 358
Dallas 336
Tokyo 332
Helsinki 316
Boston 307
Moscow 304
Melbourne 289
Mumbai 285
Phoenix 245
Boardman 239
New York 236
Chicago 213
Shanghai 208
Munich 194
Kent 192
São Paulo 170
Medford 164
San Diego 138
Clifton 107
Naples 106
Toronto 105
Turin 100
Paris 99
Bremen 88
Jakarta 85
Abuja 84
Da Nang 83
Bologna 82
West Jordan 78
Redondo Beach 77
Bengaluru 75
Bern 75
Guangzhou 75
Falls Church 74
Turku 73
London 71
Columbus 67
Haiphong 67
Brooklyn 64
Abidjan 63
Dearborn 63
Frankfurt am Main 63
Norwalk 63
Rio de Janeiro 62
Figino 58
Orem 57
Dong Ket 56
Palermo 56
Chennai 54
Pune 54
Izmir 52
Atlanta 51
Belo Horizonte 49
Montreal 49
Hillsboro 48
San Francisco 45
Vienna 45
Brussels 44
Denver 43
Johannesburg 43
Miano 43
Bari 41
Verona 39
Philadelphia 37
Tianjin 37
Venice 37
Barcelona 36
Washington 33
Auburn Hills 32
Totale 48.310
Salva come PNG Salva come JPEG
Nome #
2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds 425
MECHANISMS OF CYTOTOXICITY OF SELECTED ORGANOGOLD(III) COMPOUNDS 401
Effect of the SOD mimetic MnL4 on in vitro and in vivo oxaliplatin toxicity: Possible aid in chemotherapy induced neuropathy 381
Cytotoxic activity of 3-nitropyrazolo[5,1-c][1,2,4]benzotriazine derivatives: a new series of anti-proliferative agents. 378
Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. 368
Proteomic Analysis of Ovarian Cancer Cell Responses to Cytotoxic Gold Compounds 368
Uteroglobin reverts the transformed phenotype in the endometrial adenocarcinoma cell line HEC-1A by disrupting the metabolic pathways generating platelet-activating factor 366
In vitro assessment of antibody-conjugated gold nanorods for systemic injections 366
RNA sequencing reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 363
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. 361
Solution Chemistry and Cytotoxic Properties of Novel Organogold(III) Compounds 355
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways. 352
Natural compounds for cancer treatment and prevention 351
Antiproliferative effects of two gold(I)-N-heterocyclic carbene complexes in A2780 human ovarian cancer cells: A comparative proteomic study 349
Immunophenotypical markers, ultrastructure and chemosensitivity profile of metastatic melanoma cells. 346
Enhanced Efficacy of Artemisinin Loaded in Transferrin-Conjugated Liposomes versus Stealth Liposomes against HCT-8 Colon Cancer Cells 343
Farmaci antineoplastici - Farmaci inibitori della trasduzione del segnale - Farmaci inibitori di protein chinasi 341
Thymidylate synthase expression and genotype have no major impact on the clinical outcome of colorectal cancer patients treated with 5-fluorouracil 341
Emerging drugs in refractory colorectal cancer 340
The complex metabolic network gearing the G1/S transition in leukemic stem cells: Hints to a rational use of antineoplastic agents. 333
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. 331
Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipy(c.) 329
Druggable Targets in Pancreatic Adenocarcinoma 325
HLA-G 3'UTR Polymorphisms Impact the Prognosis of Stage II-III CRC Patients in Fluoropyrimidine-Based Treatment 315
Proteomic analysis of the cytotoxic effects induced by the organogold(III) complex Aubipyc in cisplatin-resistant A2780 ovarian cancer cells: further evidence for the glycolytic pathway implication 311
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic Acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. 308
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 299
MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin 290
Analysis of Gene Expression Profiles Reveals Novel Correlations With the Clinical Course of Colorectal Cancer 278
Epigenetics and chemoresistance in colorectal cancer: An opportunity for treatment tailoring and novel therapeutic strategies 276
Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer 262
Selection and characterization of a human ovarian cancer cell line resistant to auranofin 262
Mutations of the APC gene in human sporadic colorectal cancers. 261
Chemistry and Biology of Two Novel Gold(I) Carbene Complexes as Prospective Anticancer Agents 255
Association of the HLA-G 3′UTR polymorphisms with colorectal cancer in Italy: a first insight 252
RNA sequencing reveals PNN and KCNQ1OT1 as predictive biomarkers of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 249
[Medical therapy of malignant melanoma] 247
Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression 247
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 247
Cellular pharmacology of gemcitabine. 241
Multidrug resistance (MDR) reversers: High activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine aryl esters 240
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 240
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 236
N,N-bis(cyclohexanol)amine aryl esters: a new class of highly potent Pgp-dependent multidrug resistance (MDR) inhibitors 231
Cytotoxic properties of a new organometallic platinum(II) complex and its gold(I) heterobimetallic derivatives. 227
MOLECULAR CHARACTERIZATION OF ESTABLISHED HUMAN COLON CARCINOMA CELL LINES (HCT-8) MADE RESISTANT TO 5-FLUOROURACIL BY DIFFERENT SELECTION SCHEDULES 225
A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy. 225
Editorial: multidrug resistance in cancer: pharmacological strategies from basic research to clinical issues. 224
Biological properties of two gold(III) complexes: AuCl3(Hpm) and AuCl2(pm) 221
Exploratory Genome-Wide Association Analysis to Identify Pharmacogenetic Determinants of Response to R-CHOP in Diffuse Large B-Cell Lymphoma 220
Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. 220
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. 220
Treatment of locally advanced hepatocellular carcinoma by hepatic intra-artery chemotherapy: a pilot study. 219
New structure–activity relationship studies in a series of N,N-bis(cyclohexanol)amine aryl esters as potent reversers of P-glycoprotein-mediated multidrug resistance (MDR) 218
LIPOSOMES LOADED WITH BERBERINE HYDROCHLORIDE: DEVELOPMENT, OPTIMISATION AND IN VITRO CITOTOXICITY 218
A novel inward-rectifying K+ current with a cell-cycle dependence governs the resting potential of mammalian neuroblastoma cells. 215
Identification Of Pharmacogenomic Markers Of Clinical Efficacy In A Dose-Dense Therapy Regimen (R-Chop14) In Diffuse Large B Cell Lymphoma 215
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 211
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 211
THE IMPACT OF GENETIC POLYMORPHISMS ON R-CHOP EFFICACY IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: AN INTERIM ANALYSIS OF A MULTICENTER PROSPECTIVE PHARMACOGENETIC STUDY 210
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin 210
Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study. 209
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 209
Intracellular enhancement of intact antisense oligonucleotide steady-state levels by cationic lipids 208
Monitoring surface contamination for thirty antineoplastic drugs: a new proposal for surface exposure levels (SELs) 207
Structure, solution chemistry, antiproliferative actions and protein binding properties of non-conventional platinum(II) compounds with sulfur and phosphorus donors. 207
Role of Genetic Polymorphisms on Response to R-CHOP regimen in Diffuse Large B-cell Lymphoma Patients: an Interim Analysis of a Multicenter Prospective Pharmacogenetic Study 206
Update of NGS analysis of Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 205
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 203
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 203
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study 203
Gold(III) complexes with 2-substituted pyridines as experimental anticancer agents: Solution behavior, reactions with model proteins, antiproliferative properties 201
Trabectedin in combination with pegylated liposomal doxorubicin in patients with ovarian tumors 201
Cytotoxicity and DNA binding properties of a chloro glycylhistidinate gold(III) complex (GHAu). 199
Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. 198
The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics 194
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 194
Germline mutations in MSH2 and ATM gene in patients with GIST (gastrointestinal stromal tumor) and second epitelial tumors 194
Pharmacogenetics: Implementing personalized medicine 193
Clinical outcomes and safety of patients treated with NAb-Paclitaxel plus Gemcitabine in metastatic pancreatic cancer: the NAPA study 193
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 192
Retrospective analysis of 77 patients with ovarian cancer undergoing genetic testing for BRCA1 and BRCA2 mutations 190
Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. 190
Role of genetic polymorphisms on R-CHOP efficacy in diffuse large B-cell lymphoma patients: an interim analysis of a multicenter prospective pharmacogenetics study. 189
Inflammation in Urological Malignancies: The Silent Killer 188
Chromosomal characterization of methotrexate-resistant human T-lymphoblast leukemia cells (CCRF-CEM) with impaired polyglutamylation. 188
Correlation between thymidylate synthase (TS) mRNA expression and TS gene promoter polymorphisms in primary colorectal cancer patients 188
Role of Non-Coding RNAs in Colorectal Cancer: Focus on Long Non-Coding RNAs 187
Italian survey of second tumors in patients with diagnosis of GIST (gastrointestinal stromal tumor) 186
Immune checkpoint inhibitor-induced neurologic toxicity: a case report and literature review 185
PNN and KCNQ1OT1 can predict the efficacy of adjuvant fluoropyrimidine-based chemotherapy in colorectal cancer patients 185
Cytotoxic effects of gold(III) complexes on established human tumor cell lines sensitive and resistant to cisplatin 184
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer 184
Adverse drug reactions in oncoLogy: intEnsive monitoring program on drug toXicity of biotechnological medicatioNs anD taRget therapies in Oncologic patientS - the ALEXANDROS observational study 183
Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma 183
Inhibitory effect of luteinising hormone-releasing hormone analogues on human endometrial cancer in vitro. 182
Cabozantinib in advanced non-clear-cell renal cell carcinoma: is it the way clearer now? 182
Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2'-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives 181
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 181
Platinum-based chemotherapy in metastatic prostate cancer: what possibilities? 179
Totale 25.003
Salva come PNG Salva come JPEG
Categoria #
all - tutte 214.491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 214.491
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.970 0 0 0 99 78 160 85 212 144 102 403 687
2022/20237.370 607 1.087 244 652 631 1.473 976 451 837 51 174 187
2023/20243.071 137 286 537 118 195 449 174 664 67 185 137 122
2024/202518.969 804 2.152 1.154 2.844 5.115 2.425 278 774 1.096 481 821 1.025
2025/202624.537 2.588 3.610 2.842 2.734 2.235 776 2.700 1.076 1.458 1.245 570 2.703
2026/20274.553 742 990 2.081 740 0 0 0 0 0 0 0 0
Totale 75.110